OCT 10, 2018 7:30 AM PDT

Keynote Presentation: Proteogenomics and Cancer Biology: Insights for Prognosis and Therapy

Speaker
  • Director and Professor, Biological Sciences Division, Pacific Northwest National Laboratory
    Biography
      Dr. Karin Rodland joined the Biological Sciences Division at the Pacific Northwest National Laboratory in October 2001, after serving seventeen years on the faculty of Oregon Health Sciences University. As Chief Scientist for Biomedical Research at PNNL, she has promoted the application of PNNL's traditional strengths in mass spectrometry, proteomics, and systems biology to important problems in biomedical research. She is currently the PNNL co-Director of the OHSU-PNNL Precision Medicine Innovation CoLaboratory, a joint effort dedicated to improving patient outcomes through the integration of cutting edge technologies in integrated omics, imaging, and data analysis to advance the goals of precision medicine.
      Dr. Rodland's own research focuses on signal transduction pathways that regulate proliferation in normal and malignant cells. She was the first to recognize the role of the calcium-sensing receptor in modulating proliferation in response to small molecules in the extracellular environment. Since joining PNNL, she has adopted a systems biology approach to signal transduction and has become a recognized expert in the field of proteomics and cancer biomarkers. She is a full member of the National Cancer Institute's Early Detection Research Network, and is the chair of the Clinical Proteomics Tumor Analysis Consortium Steering Committee. She has served as Chair of the Cancer Biomarkers Study Section for the NIH, as well as the Department of Defense Congressionally Directed Medical Research Program Integration Panels for both Ovarian and Breast Cancer Research.

    Abstract

    Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids – DNA, RNA and their modifications – and a focus on proteins and protein function. Proteogenomics represents a fusion of those two approaches, leveraging the strengths of each to provide a more integrated vision of the flow of information from DNA to RNA to protein and eventually function at the molecular level. Proteogenomic studies have been incorporated into multiple activities associated with precision oncology, demonstrating substantial added value. Innovative study designs integrating genomic, transcriptomic and proteomic data, particularly those using clinically relevant samples and involving clinical trials, are poised to provide new insights regarding cancer risk, progression, and response to therapy.

    Learning Objectives: 

    1. Understand the value-added of including protein measurements with genomics and transcriptomics
    2. Understand the importance of pathway-level analysis


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    OCT 10, 2018 7:30 AM PDT

    Keynote Presentation: Proteogenomics and Cancer Biology: Insights for Prognosis and Therapy


    Specialty

    Cancer Research

    Molecular Biology

    Molecular Diagnostics

    Biomarkers

    Bioinformatics

    Genetics

    Molecular Genetics

    Cell Biology

    Pcr/rt-Pcr/real-Time Pcr

    Oncology

    Gene Sequencing

    Gene Expression

    Antibodies

    Immunology

    Cancer Diagnostics

    Geography

    North America43%

    Asia29%

    Europe29%

    Registration Source

    Website Visitors100%

    Job Title

    Student33%

    Clinical Laboratory Scientist17%

    Biologist17%

    Research Scientist17%

    Medical Laboratory Technician17%

    Organization

    Academic Institution43%

    Hospital14%

    Manufacturer - Other14%

    Contract Research Organization (Cro)14%

    Other14%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more